Posted on July 26, 2021 by Sitemaster
As of Friday (July 22), we had received more than 250 responses to our brief survey on research into active surveillance. Most of these are from patients and some from their familial supporters (spouses, partners, etc.). However,we are still interested in getting more input — especially from clinicians, including specialists, generalists, and allied health personnel like urology nurses! … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, AS, research | 2 Comments »
Posted on September 22, 2021 by Sitemaster
Prostate Cancer International (PCaI) is proud to be an inaugural member of the new Prostate Cancer Impact Alliance (PCIA). PCIA’s shared vision is to advance education, research and equitable access to high quality care to better patient outcomes for men with prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: advocacy, alliance, outcome, PCIA | 4 Comments »
Posted on September 21, 2021 by Sitemaster
Two educational programs are scheduled on Wednesday, September 29. The two programs will be be very different: one for very early stage patients; the other for patients with progressive prostate cancer at risk for (or already diagnosed with) de novo metastatic, hormone-sensitive prostate cancer (mHSPC) … READ MORE …
Filed under: Uncategorized | Leave a comment »
Posted on August 19, 2021 by Sitemaster
The decision about whether or not to treat the entire pelvic lymph node area along with the prostate (called whole pelvic radiation therapy or WPRT) or to treat just the prostate with a margin around it (called prostate-only radiation therapy or PORT) has long been a matter of judgment. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: outcome, pelvic, prostate-only, radiation, risk | 9 Comments »
Posted on August 19, 2021 by Sitemaster
A new paper by Meissner et al. has reported important, long-term data on fear of recurrence and biochemical progression of prostate cancer among a large cohort of German patients undergoing radical prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: fear, outcome, recurrence, surgery, survey | 3 Comments »
Posted on August 12, 2021 by Sitemaster
For many years your sitemaster has been advising patients that overly early use of androgen deprivation therapy (ADT) in many men with progressive prostate cancer is not necessarily the best decision (for a number of possible reasons). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, deprivation, initiation, metastasis., timing | 5 Comments »
Posted on August 11, 2021 by Sitemaster
In 2016, we looked at the Candiolo risk stratification system for radiation therapy. To our knowledge, it has not been prospectively validated or widely adopted. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: nomogram. radiation, predictive, prognosis, risk, stratification, therapy | 4 Comments »
Posted on July 26, 2021 by Sitemaster
Three more upcoming webinars this week will deal with (a) the work-up of men with prostate cancer prostate cancer who progress after first-line therapy (such as surgery, radiation, etc.); (b) whether Gleason 6 disease should really be defined as “prostate cancer”; and (c) an update on the most current information related to the evaluation and management of men with prostate cancer appropriate for active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: progression. active, surveillance, webinar | Leave a comment »
Posted on June 23, 2021 by Sitemaster
Three upcoming webinars deal with (a) the diagnosis and work-up of clinically significant forms of localized prostate cancer; (b) handling anxiety and related issues for men on active surveillance (AS); and (c) whether AS is appropriate for African Americans and others of African ethnicity. See below for details. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: education, patient, webinar | 1 Comment »
Posted on June 22, 2021 by Sitemaster
A diverse group of patients, patient advocates, patient spouses/supporters, physicians, and other researchers has come together, with funding support from the Patient Centered Outcomes Research Institute (PCORI), to plan a virtual conference for the fall of 2021. At that conference, we intend to discuss and identify new and evolving opportunities for research into the most appropriate, high-need, high-impact topics affecting the use of active surveillance (AS) for the management of favorable-risk forms of prostate cancer (i.e., low-risk and “favorable” intermediate-risk disease). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, research, surveillance | 5 Comments »
Posted on June 20, 2021 by Sitemaster
Back in 1989, the SWOG 8494 trial first showed that adding an antiandrogen (flutamide) to bilateral medical orchiectomy with an LHRH agonist (leuprolide acetate) extended median overall survival (OS) by 7 months in newly diagnosed men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone-sensitive, metastatic, mHSPC, overall, survival, SWOG 1216 | 1 Comment »
Posted on June 20, 2021 by Sitemaster
A large randomized clinical trial, SAKK 09/10, found that a salvage radiation dose of 64 Gy over 32 treatments had equivalent biochemical outcomes compared to 70 Gy over 35 treatments. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: radiation, SAKK 09/10, salvage | Leave a comment »
Posted on June 5, 2021 by Sitemaster
As we’ve seen, brachy boost therapy seems to have the best oncological results for men with very high-risk prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: ADT, brachy boost, high-risk, hormonal therapy, radiotherapy | 1 Comment »
Posted on June 3, 2021 by Sitemaster
Earlier today, Novartis issued a media release giving the major results of the Phase III VISION trial, which compared the effectiveness of 177Lu-PSMA-617+ best standard of care (SOC), as selected by individual investigators, to SOC alone in the treatment of men with PSMA-positive men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: 177Lu-PSMA-617. VISION, castration-resistant, mCRPC, metastatic, trial | 1 Comment »
Posted on May 31, 2021 by Sitemaster
The so-called PEACE-1 trial is an ongoing Phase III trial among men diagnosed with de novo metastatic castration-sensitive prostate cancer (mCSPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-sensitive, de nove, earky, mCSPC, metastatic, PEACE-1, results, rPFS, trial | 5 Comments »
